US 11,851,480 B2
Method for the production of immunoglobulin single variable domains
Peter Schotte, De Pinte (BE); and Manu De Groeve, Nieuwerkerken (BE)
Assigned to Ablynx N.V., Zwijnaarde (BE)
Filed by Ablynx N.V., Ghent-Zwijnaarde (BE)
Filed on Jul. 30, 2020, as Appl. No. 16/943,022.
Application 16/943,022 is a continuation of application No. 16/076,314, granted, now 10,975,141, previously published as PCT/EP2017/053034, filed on Feb. 10, 2017.
Claims priority of provisional application 62/294,470, filed on Feb. 12, 2016.
Prior Publication US 2021/0047392 A1, Feb. 18, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. C12Q 1/68 (2018.01); C07K 16/18 (2006.01); C07K 14/39 (2006.01); C12N 15/09 (2006.01); C12P 21/02 (2006.01)
CPC C07K 16/18 (2013.01) [C07K 14/39 (2013.01); C12N 15/09 (2013.01); C12P 21/02 (2013.01); C07K 2317/14 (2013.01); C07K 2317/35 (2013.01); C07K 2317/569 (2013.01); C07K 2317/94 (2013.01)] 18 Claims
 
1. A composition comprising:
(i) a first nucleic acid encoding a polypeptide comprising or essentially consisting of at least one immunoglobulin single variable domain having 4 framework regions (FR1 to FR4, respectively) and 3 complementarity determining regions (CDR1 to CDR3, respectively); and
(ii) a second nucleic acid encoding a HAC1spliced protein having the amino acid sequence of SEQ ID NO: 14.